Biotech once again showed recent relative strength on Wednesday, outperforming broad market averages. The Centient Biotech 200™ gained 45.36 points to 3481.45, a 1.32% rise. That was much stronger than the NYSE Composite, which was higher by .22%, or the Nasdaq, which gained .54%. There was news from big pharma, and several small, struggling companies also made market-moving announcements.
